BioSight closes investment from Arkin, Primera

Closely-held BioSight has closed an investment of $13-million led by Mori Arkin’s pharmaceutical investment firm, Arkin Holdings, and the U.S.-based venture firm, Primera Capital. Proceeds will be used for a multi...

American Renal

Leerink starts American Renal at outperform

Leerink Partners has launched coverage of American Renal Associates (NYSE:ARA) with an “outperform” rating and $33 price target. The stock closed at $27.71 on Friday. “Our positive thesis contemplates a forward adjusted...

Theravance Biopharma

Leerink starts Theravance Biopharma at outperform

Leerink has initiated coverage of Theravance Biopharma (NASDAQ:TBPH) with an “outperform” rating and $26 price target. The stock closed at $18.10 on Wednesday. Theravance was formed in 2014 via a spin out from Innovia...


Rodman starts Presbia at buy

Rodman & Renshaw has initiated coverage of Presbia PLC (NASDAQ:LENS) with the “buy” rating and 18-month price target of $14. The stock closed at $3.90 on Tuesday. Presbia has a novel corneal inlay product, the...


Senseonics Eversense CGM gets CE Mark

Senseonics Holdings (NYSE-MKT:SENS) has received CE Mark approval for its Eversense Continuous Glucose Monitoring (CGM) System. “The CE Mark approval is a significant accomplishment for Senseonics as this application...

Nobilis Health

Nobilis Health Q1 revenue climbs 35%

First quarter revenue for Nobilis Health (NYSE MKT:HLTH; TSX:NHC) rose 35% to a record $51.3-million, driven by increased case flow and a higher average revenue per case. In the first quarter, we invested heavily in new...


Roth reinitiates coverage of NeoGenomics at buy

Roth Capital Partners has reinitiated coverage on NeoGenomics with a “buy” rating and target price of $10, following its acquisition of Clarient from GE Healthcare. The stock closed at $8.34 on Tuesday. “We believe...


Oramed receives patent in China

Oramed Pharmaceuticals (NASDAQ:ORMP) has received an official notification of granting patent right for the company’s patent for its invention titled, “Methods and Compositions for Oral Administrations of Proteins” by...

Rodman & Renshaw

Rodman starts LabStyle Innovations at buy

Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday. LabStyle is an emerging digital health company focused on...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.